ATAI Life Sciences AG, a global biotech platform working to treat mental illnesses, has partnered with Neuronasal Inc. to develop a short-term treatment for mild Traumatic Brain Injury (mTBI) or concussion. Neuronasal’s potentially ground-breaking, proprietary treatment includes the intranasal delivery of low doses of N-acetylcysteine (NAC) to patients with acute mTBI. NAC is a well-established compound that has been used safely for decades, mostly as a mucolytic and to treat acute para...